Alpha Teknova (NASDAQ:TKNO - Get Free Report) will release its earnings data after the market closes on Thursday, November 7th. Persons interested in participating in the company's earnings conference call can do so using this link.
Alpha Teknova (NASDAQ:TKNO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The business had revenue of $9.61 million during the quarter, compared to the consensus estimate of $9.50 million. Alpha Teknova had a negative net margin of 98.08% and a negative return on equity of 37.00%. During the same period in the previous year, the firm posted ($0.25) earnings per share. On average, analysts expect Alpha Teknova to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Alpha Teknova Stock Performance
NASDAQ TKNO traded down $0.31 on Thursday, reaching $6.80. 208,616 shares of the company's stock traded hands, compared to its average volume of 223,680. The firm has a market cap of $362.46 million, a price-to-earnings ratio of -7.31 and a beta of 0.43. The stock has a 50 day moving average price of $5.28 and a 200-day moving average price of $3.31. Alpha Teknova has a fifty-two week low of $1.15 and a fifty-two week high of $7.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.28 and a current ratio of 4.76.
Analysts Set New Price Targets
Separately, Stephens reiterated an "overweight" rating and issued a $5.00 price objective on shares of Alpha Teknova in a research report on Wednesday, July 10th.
Check Out Our Latest Analysis on TKNO
Alpha Teknova Company Profile
(
Get Free Report)
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Read More
Before you consider Alpha Teknova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.
While Alpha Teknova currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.